Placebo + EMBEDA - morphine sulfate/ naltrexone hydrochloride + morphine sulfate CR crushed.
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Narcotic Abuse
Conditions
Narcotic Abuse, Opioid-related Disorders, Analgesia, Chronic Pain
Trial Timeline
Aug 1, 2010 → Jan 1, 2011
NCT ID
NCT01595867About Placebo + EMBEDA - morphine sulfate/ naltrexone hydrochloride + morphine sulfate CR crushed.
Placebo + EMBEDA - morphine sulfate/ naltrexone hydrochloride + morphine sulfate CR crushed. is a phase 1 stage product being developed by Pfizer for Narcotic Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT01595867. Target conditions include Narcotic Abuse, Opioid-related Disorders, Analgesia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01595867 | Phase 1 | Completed |
Competing Products
1 competing product in Narcotic Abuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aprepitant 0mg + Aprepitant 40mg + Aprepitant 200mg + Oxycodone 0mg, p.o. + Oxycodone 20mg, p.o. + Oxycodone 40mg, p.o. + Oxycodone 0mg, IN + Oxycodone 15mg, IN + Oxycodone 30mg, IN | Merck | Pre-clinical | 23 |